Objective:

This study seeks to assess the impact of piracetam on overall cognitive function in adults with memory impairment compared to a placebo.

Background:

Piracetam, a widely recognized nootropic drug, is hypothesized to enhance memory function through its influence on synaptic plasticity and neurotransmitter levels. However, despite its popularity, there remains a lack of conclusive evidence regarding its impact on cognition and memory. Therefore, the present study aims to explore the effects of piracetam on memory in individuals with impaired cognitive function, comparing it to a placebo control group.

Design/Methods:

We conducted an extensive bibliographic review and performed a meta-analysis of clinical trials that examined memory function in individuals taking piracetam as opposed to those in the placebo group. The study encompassed a thorough search of databases including PubMed, Dimensions, Embase, and the Cochrane Library. Data analysis was executed using R Studio version 4.3.1.

Results:

In our analysis, 199 articles were identified, of which we included eighteen studies, comprising a total of 886 patients, of which Piracetam was the treatment option in 442 (49.88%) patients. Memory enhancement (SMD 0.75; 95% CI [−0.19; 1.69]; p=0.12; I²=96%) had no clinical difference between the intervention and the control group.

Conclusions:

Upon the conclusion of this study, it is apparent that we cannot definitively ascertain the impact of piracetam on memory function. Further research is warranted to provide a clearer understanding of the cognitive effects of piracetam in individuals with memory impairment. This investigation serves as a significant contribution to the ongoing quest to elucidate the potential benefits of piracetam in the field of cognitive neuroscience.